Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use

BACKGROUND Desmoid-type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health-related quality of life (HRQoL) and healthcare use (univariate and multivariate). METHODS Desmoid-type fibromatosis patients from the United Kingdom and the Netherlands received cross-sectional questionnaires on HRQoL (EORTC QLQ-C30), DTF-specific HRQoL (DTF-QoL) and healthcare utilisation. Latent class cluster analysis was performed to identify subgroups based on patients' symptom burden using EORTC QLQ-C30 and DTF-QoL physical symptom items. Multivariate linear and logistic regression analyses were conducted to examine associations of symptom burden with HRQoL and healthcare utilisation, respectively. RESULTS Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden-low pain (20%), intermediate symptom burden-high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF-related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation. CONCLUSIONS This study identified four distinct subgroups of DTF patients based on their level of symptom burden, with a considerable number of patients being highly symptomatic. Knowledge of the level of symptom burden DTF patients experience can help to identify patients at risk of poorer outcomes and tailor supportive care to the individual needs of DTF patients.

[1]  M. Gounder,et al.  1488MO Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT) , 2022, Annals of Oncology.

[2]  R. Riedel,et al.  LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT) , 2022, Annals of Oncology.

[3]  Robin L. Jones,et al.  Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes , 2022, Cancers.

[4]  Robin L. Jones,et al.  Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis , 2022, Cancers.

[5]  Robin L. Jones,et al.  The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study , 2021, Cancers.

[6]  S. Sleijfer,et al.  Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries , 2020, Sarcoma.

[7]  Robin L. Jones,et al.  The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.

[8]  Peter Jeffrey Jordan,et al.  Common method bias in applied settings: The dilemma of researching in organizations , 2020, Australian Journal of Management.

[9]  Robin L. Jones,et al.  Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance , 2019, Annals of Surgical Oncology.

[10]  P. Fayers,et al.  General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. , 2019, European journal of cancer.

[11]  D. Boll,et al.  Illness perceptions are associated with higher health care use in survivors of endometrial cancer—a study from the population-based PROFILES registry , 2018, Supportive Care in Cancer.

[12]  L. V. van de Poll-Franse,et al.  Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: the population-based PROFILES registry , 2018, Quality of Life Research.

[13]  Robin L. Jones,et al.  Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? , 2018, Supportive Care in Cancer.

[14]  S. Sleijfer,et al.  Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study , 2018, Quality of Life Research.

[15]  L. Traeger,et al.  The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer , 2017, Cancer.

[16]  J. Blay,et al.  Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. , 2017, European journal of cancer.

[17]  J. Blay,et al.  Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. , 2016, European journal of cancer.

[18]  Helen Skerman,et al.  Latent Class Analysis Reveals Distinct Subgroups of Patients Based on Symptom Occurrence and Demographic and Clinical Characteristics. , 2015, Journal of pain and symptom management.

[19]  M. D. den Bakker,et al.  Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study , 2015, Annals of surgical oncology.

[20]  Philippe Rigaux,et al.  Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. , 2015, Bulletin du cancer.

[21]  S. Bonvalot,et al.  Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought , 2013, Annals of Surgical Oncology.

[22]  G. Rodin,et al.  The relationship between depression and physical symptom burden in advanced cancer , 2013, BMJ Supportive & Palliative Care.

[23]  J. Coebergh,et al.  The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. , 2011, European journal of cancer.

[24]  J. Suls,et al.  The symptom perception hypothesis revised: depression and anxiety play different roles in concurrent and retrospective physical symptom reporting. , 2011, Journal of personality and social psychology.

[25]  M. Dodd,et al.  The effect of symptom clusters on functional status and quality of life in women with breast cancer. , 2010, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[26]  D. Pud,et al.  The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. , 2008, Journal of pain and symptom management.

[27]  J. Coebergh,et al.  Increased health care utilization among long‐term cancer survivors compared to the average Dutch population: A population‐based study , 2007, International journal of cancer.

[28]  F. Rodríguez‐Artalejo,et al.  Gender differences in the utilization of health-care services among the older adult population of Spain , 2006, BMC public health.

[29]  L. Frostholm,et al.  The Patients’ Illness Perceptions and the Use of Primary Health Care , 2005, Psychosomatic medicine.

[30]  M. Liang,et al.  The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. , 2003, Arthritis and rheumatism.

[31]  J. Robbins,et al.  Gender differences in the utilization of health care services. , 2000, The Journal of family practice.

[32]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.